Sarepta Therapeutics(SRPT)股价在周一夜盘大跌8.78%，报收于12.89美元。此次暴跌主要源于该公司主打基因疗法Elevidys的安全性问题和监管风险的持续发酵。
近期，Sarepta的基因疗法在临床试验中出现第三例患者死亡事件，引发了市场对其安全性的担忧。更为棘手的是，美国食品药品监督管理局(FDA)要求Sarepta停止Elevidys的发货，但公司拒绝了这一要求，这一举动可能加剧了与监管机构的紧张关系。洛杉矶儿童医院已宣布暂停对所有患者使用Elevidys，这可能会影响药物的市场推广。
受此影响，多家券商下调了Sarepta的股票评级和目标价。Mizuho将Sarepta从"买入"降至"中性"，目标价从40美元大幅下调至14美元。Leerink更是将评级从"跑赢大盘"下调至"与大盘持平"，目标价从45美元降至10美元。分析师们普遍表示，对公司管理层处理安全问题的方式以及与FDA的关系表示担忧，这些因素可能会影响Sarepta的长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.